IgA Nephropathy News and Research

RSS

IgA nephropathy (IgAN), also known as Berger’s disease, is the leading cause of primary glomerulonephritis all over the world. It is autoimmune in origin, characterized by the stimulation of genetically determined formation of concentration of IgA1 with galactose-deficient O-glycans in the hinge-region (Hit 1) in the blood. These stimulate anti-glycan antibody production, followed by binding with the aberrantly glycated IgA1.

Study finds low absolute risk of glomerular disease relapse associated with COVID-19 vaccination

Several reports have described a relapse of certain autoimmune kidney diseases in patients after they've received COVID-19 vaccines, but it's unclear if this association is real or a coincidence.

4 Nov 2022

Adults with primary glomerular disease have high cardiovascular risk, study shows

Among almost 2,000 adults with primary glomerular disease followed for a median of 6.8 years, risk of cardiovascular events including coronary artery, cerebrovascular, and peripheral vascular events, and death due to myocardial infarction or stroke was 2.5-fold higher compared to the general population.

1 Jun 2022

Study shows glomerulonephritis after SARS-CoV-2 mRNA vaccination likely coincidental

In a recent study posted to the medRxiv* pre-print server, researchers assessed whether messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines increase the incidence of glomerulonephritis against the null hypothesis stating any observed temporal association between the two phenomena was purely coincidental.

26 May 2022

Multi-country study provides a clear treatment option for IgA nephropathy

The largest ever randomized controlled trial in IgA nephropathy has found that treatment with methylprednisolone - a cheap, widely used corticosteroid drug - halves the risk of losing kidney function and kidney failure, and that this can be effectively achieved with fewer side effects if a reduced dose is used.

17 May 2022

Pioneering kidney disease research at Leicester receives a major boost on World Kidney Day

Pioneering research by the University of Leicester into chronic kidney disease has received a major boost on World Kidney Day (10th March 2022) following a generous £1million donation from long-term supporter and kidney health advocate Jimmy Mayer.

10 Mar 2022

Study evaluates the potential benefits of mass dipstick screening to detect hematuria

As the saying goes, "the sooner the better," and such is the case for the detection of kidney and urological diseases. Early detection is key, and may be achieved through the use of a dipstick urine test.

4 Feb 2022

Results of high-impact clinical trials could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online at ASN Kidney Week 2021 November 4–November 7.

7 Nov 2021

Study reports safety, efficacy of targeted treatment for IgA nephropathy

IgA nephropathy (IgAN) is a chronic kidney disease occurring in young adults and is one of the most common reasons for kidney transplantation in this age group.

7 Jun 2021

Repurposed drug for acute lung injury in COVID-19

Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.

2 Jul 2020

Low socioeconomic status associated with certain kidney diseases

A new study found an inverse association between socioeconomic status and certain kidney diseases. The findings appear in an upcoming issue of CJASN.

20 Feb 2020

UAB researchers find key role for IgG autoantibodies in IgA nephropathy

The most common form of the kidney disease called glomerulonephritis is IgA nephropathy.

24 Sep 2019

Omeros’ OMS721 receives positive opinion from EMA's COMP for treating hematopoietic stem cell transplant

Omeros Corporation announced today that the European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion recommending orphan drug designation of OMS721 for treatment in hematopoietic stem cell transplantation.

25 Jul 2018

Worldwide study to examine new treatments for IgA nephropathy

A patient from Birmingham is the first person to be recruited into a new worldwide study to test new treatments for a potentially life-threatening kidney condition called IgA nephropathy.

28 Jun 2018

Omeros’ OMS721 receives orphan drug designation from FDA for treatment of IgA nephropathy

Omeros Corporation today announced that OMS721 has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Immunoglobulin A (IgA) nephropathy.

4 Aug 2017

Scientists identify genetic clues to chronic kidney disease

Using international genomic studies backed by proof-of-concept cell experiments, researchers have identified two genes that contribute to the chronic kidney disease glomerulonephritis.

16 Mar 2017

Researchers uncover new genetic clues linked to autoimmune kidney disease

Researchers have uncovered new genetic clues to understanding IgA nephropathy (IgAN), or Berger's disease, an autoimmune kidney disease and a common cause of kidney failure.

6 Mar 2017

Researchers discover strong genetic risk factor for IgA nephropathy

An international research collaboration has discovered a strong genetic risk factor for IgA nephropathy (IgAN) - the most common inflammatory kidney disease worldwide - and related renal dysfunction.

14 Jul 2016

Study links alpha-defensin genes to IgA nephropathy risk

A gene which forms part of our body's first line of defence against infection may be associated with an increased risk with a type of kidney disease, research involving academics at The University of Nottingham has discovered.

30 Jun 2016

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Pharmalink AB, a specialty pharma company, today announces that the NEFIGAN Trial of Nefecon for the treatment of primary IgA nephropathy has fully met its primary efficacy endpoint at a planned interim analysis and been stopped early with respect to statistical analysis of the endpoint.

14 Apr 2015

Pharmalink AB acquires anti-inflammatory drug candidate from Synartro AB

Pharmalink AB, a specialty pharma company, announces that it has acquired a novel product candidate in development for treating inflammation from Synartro AB. No financial details are disclosed.

18 Mar 2015